Browsing: Biologics

SHANGHAI, April 17, 2023 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269. HK), a leading global Contract Research, Development,…

Revenue Increased by 48.4% Y-o-Y to RMB15,268.7 Million Gross Profit Increased by 39.2% Y-o-Y to RMB6,724.0 Million Adjusted Net…

U.S. stocks traded lower, with the Dow Jones dropping over 600 points on Thursday. Here are some big…

Revenue Increased by 63.5% Y-o-Y to RMB7,206.4 Million Gross Profit Increased by 48.6% Y-o-Y to RMB3,413.2 Million Net Profit…

WuXi Biologics Continues Strong Business Momentum for Sustainable High Growth in 2022 Recap from the Fourth Investor Day…

Banner Year for Commercial Manufacturing Revenue Increased by 83.3% Y-o-Y to RMB10,290.1 Million Gross Profit Increased by 90.6%…

Revenue Increases by 126.7% Y-o-Y to RMB4,406.8 Million Gross Profit Grows by 191.7% Y-o-Y to RMB2,296.8 MillionAdjusted Net…

WuXi Biologics and WuXi STA have established a joint venture company named WuXi XDC to provide contract development…